Patient Advocacy

Patient Centricity: Our Commitment to Patient Care and Medicines Innovation

At Daiichi Sankyo Europe, our motto 'Passion for Innovation. Compassion for Patients' extends beyond the development of medicines. Patient centricity is a key component in how we think and work.

By adopting a mindset that is centered on caring for patients we understand that:

1. people are experts in their own condition and have a unique perspective about the healthcare and wellbeing outcomes that matter to them
2. people have the right to be involved in what impacts them, including the development of new (innovative) medicines

This commitment to incorporate patient and caregiver voices and experiences allows Daiichi Sankyo Europe to address the outcomes that matter for patients, improve patient care, and help close the gaps that exist between medicine innovation and patient centred care. Ultimately, helping us deliver on our global purpose to enrich the quality of life of people around the world.

How We Work with Patients: Patient Advocacy and Collaboration for Better Health Outcomes

At Daiichi Sankyo Europe we work with Patient Organisations, Patients, and their Caregivers, to support their priorities. In recognising the variety of patient experiences and needs, Daiichi Sankyo Europe aspires to develop more effective healthcare solutions that focus on patient care.

Grants, Donations & Sponsorships

Daiichi Sankyo Europe is committed to supporting projects, initiatives, and concepts which enhance patient support or benefit and maintain sustainable, high-quality care for patients. This could include provision of funding to patient groups or charitable organisations which aim to extend Patient Advocacy by improving awareness amongst clinicians, patients, and the public, within the oncology and cardiovascular disease therapy areas.

All Grants, Donations & Sponsorships are provided on application merit and are not allocated based on any perceived or expected financial material benefit to the Daiichi Sankyo Europe organisation. All funding approval is at the discretion of Daiichi Sankyo Europe and the request for funding should be within one of our focus disease areas of oncology and cardiovascular disease.

If support is provided through a Grant, Donation or Sponsorship a written agreement will confirm the terms of the arrangement. All support must be appropriately declared for transparency and made apparent on any materials associated with the activity e.g., educational items or materials used. In line with the requirements of the European Federation of Pharmaceutical Industries (EFPIA) Code of Practice for the Pharmaceutical Industry, details of funding (transfer of value) provided by Daiichi Sankyo Europe will be publicly disclosed annually in the country where the organisation receiving the funding is registered.

Contact us with any further questions about the activities we are engaged in: PatientAdvocacy@daiichi-sankyo.eu